Progress of Research on Glucagon-like Peptide and Dipeptidyl Peptidase-4 Inhibitor in Treatment of Inflammatory Bowel Disease
10.3969/j.issn.1008-7125.2023.11.007
- VernacularTitle:胰高血糖素样肽和二肽基肽酶-4抑制剂在炎症性肠病治疗中的研究进展
- Author:
Keke ZHAO
1
;
Hongliang GAO
Author Information
1. 新疆医科大学第一附属医院消化病二科(830054)
- Keywords:
Glucagon-Like Peptide 1;
Glucagon-Like Peptide 2;
Dipeptidyl Peptidase-4 Inhibitor;
Inflammatory Bowel Disease;
Therapy
- From:
Chinese Journal of Gastroenterology
2023;28(11):683-687
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease(IBD)is a non-specific and easily recurrent chronic inflammatory disease of the intestine,mainly including ulcerative colitis(UC)and Crohn's disease(CD).Its etiology and pathogenesis have not been fully elucidated,but it is currently believed to be related to environmental,genetic,immune response abnormalities,and other factors.At present,IBD has become a disease of great concern worldwide.According to the epidemiological data and data of inflammatory bowel disease in China,the incidence rate of IBD is on the rise year by year in China,but so far,there has not been a drug that can completely cure the disease.Recently,glucagon-like peptide(GLP)and its degradation enzyme inhibitor dipeptidyl peptidase-4(DPP-4)inhibitors have attracted widespread research and attention in the treatment of IBD.This article reviewed the roles and mechanisms of GLP and DPP-4 inhibitors in the treatment of IBD diseases.
